Hard To Treat Diseases (HTDS) Negotiating to Merge with a UK Health Ca...( LONDON UK Feb. 13 / Hard to Treat Dis...),Health

LONDON, UK, Feb. 13 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS) (www.htdsmedical.com) has entered negotiations to merge with a health care UK based company that has developed a radically new product which is marketed in many European countries, and already has the FDA approval (or authority equivalent to the specific country). The product employs food grade ingredients that are FDA approved.

HTDS Andrea Zecevic-Rubio, Chief Project Scientist, Director, R&D, noted, "I'm speaking purely from a scientific and medical stance. This was an opportunity that came up earlier last month in my research. We immediately dispatched Company representatives to pursue negotiations on a corporate level. We are very encouraged by the results to date. We think this UK health care company has a tremendous upside as it truly is a new approach to the health care services they offer. Furthermore this company already sells their product in market, and given the fact that it is a drug-free approach it currently is made available in pharmacies and other similar type locations."

Negotiations are continuing in the U.K., and the Company hopes to make more definitive announcements on this matter by early March. The planned merger with Mellow Hope is unaffected by these recent events other than the fact that HTDS will become more of a medical conglomerate when both the UK and China mergers are complete. The UK company reports its revenues in Sterling and has gross revenue sales of about 2 million USD.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

Get the Facts Right. The issu
'/>"/>